EGFR and neoplasm: Even treatment approach was similar in the two sexes: independently from gender and tumor location, 70% of patients with RAS wt tumors received anti-EGFR agents (Cetuximab or Panitumumab) in association with the standard chemotherapy backbone, while most patients with RAS mut tumors (71%) received Bevacizumab.